What do systematic reviews say?

Summary of findings 2: PLD alone vs other conventional chemotherapy

It is very uncertain whether summary of findings 2: PLD alone changes neurological (grade ≥ 3) compared with other conventional chemotherapy (very low certainty).

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1222 participants
  Very low

Summary of findings 2: PLD alone vs other conventional chemotherapy

Summary of findings 2: PLD alone showed no clear difference in overall survival (OS) compared with other conventional chemotherapy (moderate certainty).

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.96 [0.77, 1.19]
  6 studies · 1995 participants
  Moderate

Summary of findings 2: PLD alone vs other conventional chemotherapy

It is very uncertain whether summary of findings 2: PLD alone changes progression‐free survival (PFS) compared with other conventional chemotherapy (very low certainty).

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.94 [0.85, 1.04]
  4 studies · 1803 participants
  Very low

Summary of findings: ACBT vs PEP mask therapy

The review found no eligible studies for this question.

• Active cycle of breathing technique for cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: ACBT vs PEP mask therapy

The review found no eligible studies for this question.

• Active cycle of breathing technique for cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: ACBT vs PEP mask therapy

The review found no eligible studies for this question.

• Active cycle of breathing technique for cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: ACBT vs PEP mask therapy

The review found no eligible studies for this question.

• Active cycle of breathing technique for cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: ACBT vs PEP mask therapy

The review found no eligible studies for this question.

• Active cycle of breathing technique for cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: ACBT vs PEP mask therapy

• Active cycle of breathing technique for cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 30 participants
  Very low

Summary of findings: ACBT vs PEP mask therapy

The review found no eligible studies for this question.

• Active cycle of breathing technique for cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Steroid implant vs standard‐of‐care therapy

• Corticosteroid implants for chronic non‐infectious uveitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Moderate

Steroid implant vs standard‐of‐care therapy

Steroid implant may leads to higher proportion of eyes with cataract formation or progression, or surgery compared with standard‐of‐care therapy (low certainty).

• Corticosteroid implants for chronic non‐infectious uveitis 2023 · Cochrane Headline outcomes only
  RR 2.71 [2.06, 3.56]
  Studies not reported
  Low

Steroid implant vs standard‐of‐care therapy

Steroid implant probably leads to higher proportion of eyes with elevated IOP or receiving intervention compared with standard‐of‐care therapy (moderate certainty).

• Corticosteroid implants for chronic non‐infectious uveitis 2023 · Cochrane Headline outcomes only
  RR 3.64 [2.71, 4.87]
  Studies not reported
  Moderate

Steroid implant vs standard‐of‐care therapy

Steroid implant showed no clear difference in proportion of eyes with endophthalmitis**** compared with standard‐of‐care therapy (moderate certainty).

• Corticosteroid implants for chronic non‐infectious uveitis 2023 · Cochrane Headline outcomes only
  RR 7.3 [0.91, 58.72]
  Studies not reported
  Moderate

Steroid implant vs standard‐of‐care therapy

Steroid implant showed no clear difference in proportion of eyes with retinal tear or detachment compared with standard‐of‐care therapy (moderate certainty).

• Corticosteroid implants for chronic non‐infectious uveitis 2023 · Cochrane Headline outcomes only
  RR 2.07 [0.51, 8.4]
  Studies not reported
  Moderate

Steroid implant vs standard‐of‐care therapy

Steroid implant may leads to lower proportion of eyes with recurrence of uveitis compared with standard‐of‐care therapy (low certainty).

• Corticosteroid implants for chronic non‐infectious uveitis 2023 · Cochrane Headline outcomes only
  RR 0.46 [0.35, 0.6]
  Studies not reported
  Low

Steroid implant vs standard‐of‐care therapy

• Corticosteroid implants for chronic non‐infectious uveitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Later vs earlier initiation of dexamethasone therapy

Later showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks' PMA compared with earlier initiation of dexamethasone therapy (low certainty).

• Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants 2023 · Cochrane Headline outcomes only
  RR 1.06 [0.87, 1.29]
  3 studies · 391 participants
  Low

Later vs earlier initiation of dexamethasone therapy

Later showed no clear difference in death or cerebral palsy at 1 to 3 years compared with earlier initiation of dexamethasone therapy (low certainty).

• Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants 2023 · Cochrane Headline outcomes only
  RR 1.12 [0.68, 1.84]
  1 study · 86 participants
  Low

Later vs earlier initiation of dexamethasone therapy

Later showed no clear difference in death or abnormal neurodevelopmental outcome (various definitions) compared with earlier initiation of dexamethasone therapy (low certainty).

• Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants 2023 · Cochrane Headline outcomes only
  RR 0.87 [0.63, 1.21]
  2 studies · 167 participants
  Low